Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.366 -0.034 (-2.41%)
Streaming Delayed Price Updated: 11:35 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗
Read the latest report on NanoViricides here 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
Via ACCESSWIRE
News headline image
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? ↗
Read the latest report on NanoViricides here. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
By David Willey, Benzinga 
Via TheNewswire.com
News headline image
Why Are NanoViricides Shares Gaining Today ↗
NanoViricides Inc (NYSE: NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical drug candidate for  
Via Benzinga
News headline image
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target? 
Via News Direct
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
By David Willey, Benzinga 
Via TheNewswire.com
News headline image
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket ↗
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday. 
Via Benzinga
News headline image
Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
Via ACCESSWIRE
News headline image
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target? ↗
Read the latest report on NanoViricides here. 
Via Benzinga
News headline image
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment 
Via News Direct
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
By David Willey, Benzinga 
Via TheNewswire.com
News headline image
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
Via ACCESSWIRE
News headline image
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment ↗
Read the latest report on NanoViricides here. 
Via Benzinga
News headline image
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
Via ACCESSWIRE
News headline image
The 7 Most Promising Penny Stocks to Buy in June ↗
These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
Via ACCESSWIRE
News headline image
NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
Via ACCESSWIRE
TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
Via Investor Brand Network
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
News headline image
NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
Via ACCESSWIRE
News headline image
NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
Via ACCESSWIRE
News headline image
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All 
Via News Direct
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.